AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 DEC 10 - (NewsRx.com & NewsRx.net) -- Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus.
According to published research from the United States, "Two molecularly engineered, live-attenuated West Nile virus (WN) vaccine candidates were highly attenuated and protective in rhesus monkeys. The vaccine candidates are chimeric viruses (designated WN/DEN4) bearing the membrane precursor and envelope protein genes of WN on a backbone of dengue 4 virus (DEN4) with or without a deletion of 30 nucleotides (Delta30) in the 3' noncoding region of DEN4."
"Viremia in WN/DEN4- infected monkeys was reduced 100-fold compared to that in WN- or DEN4-infected monkeys," reported Alexander G. Pletnev and colleagues at the National Institute of Allergy and Infectious Diseases. "WN/DEN4-3'Delta30 did not cause detectable viremia, indicating that it is even more attenuated for monkeys."
"These findings indicate that chimerization itself and the presence of the Delta30 mutation independently contribute to the attenuation phenotype for nonhuman primates," said Pletnev and his collaborators. "Despite their high level of attenuation in ...
Source: HighBeam Research, West Nile/dengue virus vaccine protect monkeys from West Nile virus.